Subscribe to RSS
In Vitro Anticancer Effects of All-trans Retinoic Acid in Combination with Dacarbazine against CD117+ Melanoma CellsFunding: This work was supported by a thesis grant for MD from Ardabil University of Medical Sciences (Grant No. 0694).
Background Malignant melanoma is a common form of skin cancer that contains different cell types recognized by various cell surface markers. Dacarbazine-based combination chemotherapy is frequently used for the treatment of melanoma. Despite its potent anticancer properties, resistance to dacarbazine develops in malignant melanoma. Here, we aim to improve response to dacarbazine therapy by pretreatment with all-trans retinoic acid (ATRA) in CD117+ melanoma cells.
Methods The CD117+ melanoma cells were sorted from A375 malignant melanoma cell line using magnetic-activated cell sorting (MACS). The cell viability was examined by cell proliferation assay (MTT). Apoptosis was determined by acridine orange/ ethidium bromide staining. Indeed, we performed flow cytometry to evaluate the cell cycle arrest.
Results Here, the CD117+ melanoma cells were incubated with various concentrations of ATRA, dacarbazine, and their combination to determine IC50 values. We found that 20 µM ATRA treatment followed by dacarbazine was found to be more effective than dacarbazine alone. There was an indication that the combination of ATRA with dacarbazine (ATRA/dacarbazine) caused more apoptosis and necrosis in the melanoma cells (P<0.05). Furthermore, ATRA/dacarbazine treatment inhibited the cell at the G0/G1 phase, while dacarbazine alone inhibited the cells at S phase.
Conclusion Collectively, combined treatment with ATRA and dacarbazine induced more apoptosis and enhanced the cell cycle arrest of CD117+ melanoma cells. These results suggested that ATRA increased the sensitivity of melanoma cells to the effect of dacarbazine.
Received: 14 June 2020
Accepted: 10 August 2020
Article published online:
06 October 2020
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Leonardi GC, Falzone L, Salemi R. et al. Cutaneous melanoma: From pathogenesis to therapy. International Journal of Oncology 2018; 52: 1071-1080
- 2 Jemal A, Ward EM, Johnson CJ. et al. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. JNCI: Journal of the National Cancer Institute 2017; 109: djx030
- 3 Matthews NH, Li W-Q, Qureshi AA et al. Epidemiology of melanoma. In: Cutaneous Melanoma: Etiology and Therapy [Internet]. Codon Publications, 2017
- 4 Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22: 3138-3151
- 5 Serrone L, Zeuli M, Sega F. et al. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. Journal of Experimental & Clinical Cancer Research: CR 2000; 19: 21-34
- 6 Khayat D, Bernard-Marty C, Meric J-B et al. Biochemotherapy for advanced melanoma: Maybe it is real. American Society of Clinical Oncology. 2002
- 7 Bajetta E, Del Vecchio M, Bernard-Marty C. et al. Metastatic melanoma: Chemotherapy. In: Seminars in Oncology 2002; 5: 427-445
- 8 Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leukemia Research 2001; 25: 571-576
- 9 Leong KG, Wang B-E, Johnson L. et al. Generation of a prostate from a single adult stem cell. Nature 2008; 456: 804-808
- 10 Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. The International Journal of Biochemistry & Cell Biology 1999; 31: 1053-1074
- 11 Foster BM, Zaidi D, Young TR. et al. CD117/c-kit in cancer stem cell-mediated progression and therapeutic resistance. Biomedicines 2018; 6: 31
- 12 Garcia JJ, Kramer MJ, Mackey ZB. et al. Utility of CD117 immunoreactivity in differentiating metastatic melanoma from clear cell sarcoma. Archives of Pathology & Laboratory Medicine 2006; 130: 343-348
- 13 Zhang H, Satyamoorthy K, Herlyn M. et al. All-trans retinoic acid (atRA) differentially induces apoptosis in matched primary and metastatic melanoma cells–a speculation on damage effect of atRA via mitochondrial dysfunction and cell cycle redistribution. Carcinogenesis 2003; 24: 185-191
- 14 Yin W, Song Y, Liu Q. et al. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8(+) T-cell immunity. Immunology 2017; 152: 287-297
- 15 Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. European Journal of Cancer 2004; 40: 1825-1836
- 16 Najafzadeh N, Mazani M, Abbasi A. et al. Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44(+) cancer stem cells. Biomedicine & Pharmacotherapy 2015; 74: 243-251
- 17 Aebi S, Kröning R, Cenni B. et al. All-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells. Clinical Cancer Research 1997; 3: 2033-2038
- 18 Mohammadi Jobani B, Najafzadeh N, Mazani M et al. Molecular mechanism and cytotoxicity of allicin and all-trans retinoic acid against CD44+ versus CD117+ melanoma cells. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology 2018; 161–169
- 19 Wood W, Seftor E, Lotan D. et al. Retinoic acid inhibits human melanoma tumor cell invasion. Anticancer Research 1990; 10: 423-432
- 20 Küley-Bagheri Y, Kreuzer KA, Monsef I et al. Effects of all trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML)(non acute promyelocytic leukaemia (non APL)). Cochrane Database of Systematic Reviews (8) 2018; 8: CD011960
- 21 Xu X-C, Liu X, Tahara E. et al. Expression and up-regulation of retinoic acid receptor-β is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. Cancer Research 1999; 59: 2477-2483
- 22 Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003; 22: 7305-7315
- 23 Adamson PC. All-Trans-Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia. The Oncologist 1996; 1: 305-314
- 24 Li C, Han X. Co-delivery of Dacarbazine and All-Trans Retinoic Acid (ATRA) Using Lipid Nanoformulations for Synergistic Antitumor Efficacy Against Malignant Melanoma. Nanoscale Research Letters 2020; 15: 1-10
- 25 Neumann I, Foell JL, Bremer M. et al. Retinoic acid enhances sensitivity of neuroblastoma cells for imatinib mesylate. Pediatric Blood & Cancer 2010; 55: 464-470
- 26 Lindner DJ, Borden EC, Kalvakolanu DV. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clinical Cancer Research 1997; 3: 931-937
- 27 Fang Y, Zhou X, Lin M. et al. The ubiquitin-proteasome pathway plays essential roles in ATRA-induced leukemia cells G0/G1 phase arrest and transition into granulocytic differentiation. Cancer Biology & Therapy 2010; 10: 1157-1167
- 28 Demary K, Wong L, Liou JS. et al. Redox control of retinoic acid receptor activity: a novel mechanism for retinoic acid resistance in melanoma cells. Endocrinology 2001; 142: 2600-2605
- 29 Chlapek P, Slavikova V, Mazanek P. et al. Why differentiation therapy sometimes fails: molecular mechanisms of resistance to retinoids. International Journal of Molecular Sciences 2018; 19: 132